U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H16ClN3O3S
Molecular Weight 365.835
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZIDAPAMIDE

SMILES

CC1N(CC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C(=C3)S(N)(=O)=O

InChI

InChIKey=BHUKYXOYJMLRAK-UHFFFAOYSA-N
InChI=1S/C16H16ClN3O3S/c1-10-13-5-3-2-4-12(13)9-20(10)19-16(21)11-6-7-14(17)15(8-11)24(18,22)23/h2-8,10H,9H2,1H3,(H,19,21)(H2,18,22,23)

HIDE SMILES / InChI
Molecular Formula C16H16ClN3O3S
Molecular Weight 365.835
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Zidapamide (1-methyl-2-(3'-sulphenyl-4'-chlorobenzamido)-isoindoline) is an isoindoline derivative exerting diuretic, salutaric and hypotensive activity.

Originator

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Patents

Patents

US4338331
1

Sample Use Guides

In Vivo Use Guide
In rodents zidapamide can be administered orally in a dose of 2.5-5 mg per day, depending upon whether it is required to utilize its hypertensive or diuretic action.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:45:43 GMT 2023
Edited
by admin
on Sat Dec 16 17:45:43 GMT 2023
Record UNII
F7KU1MIY58
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZIDAPAMIDE
INN   USAN  
USAN   INN  
Official Name English
ISODAPAMIDE
Common Name English
4-CHLORO-N-(1-METHYL-2-ISOINDOLINYL)-3-SULFAMOYLBENZAMIDE
Systematic Name English
zidapamide [INN]
Common Name English
ZIDAPAMIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C448
Created by admin on Sat Dec 16 17:45:44 GMT 2023 , Edited by admin on Sat Dec 16 17:45:44 GMT 2023
Code System Code Type Description
INN
5129
Created by admin on Sat Dec 16 17:45:43 GMT 2023 , Edited by admin on Sat Dec 16 17:45:43 GMT 2023
PRIMARY
PUBCHEM
3033626
Created by admin on Sat Dec 16 17:45:44 GMT 2023 , Edited by admin on Sat Dec 16 17:45:44 GMT 2023
PRIMARY
ChEMBL
CHEMBL6378
Created by admin on Sat Dec 16 17:45:43 GMT 2023 , Edited by admin on Sat Dec 16 17:45:43 GMT 2023
PRIMARY
NCI_THESAURUS
C82267
Created by admin on Sat Dec 16 17:45:44 GMT 2023 , Edited by admin on Sat Dec 16 17:45:44 GMT 2023
PRIMARY
USAN
U-32
Created by admin on Sat Dec 16 17:45:44 GMT 2023 , Edited by admin on Sat Dec 16 17:45:44 GMT 2023
PRIMARY
FDA UNII
F7KU1MIY58
Created by admin on Sat Dec 16 17:45:43 GMT 2023 , Edited by admin on Sat Dec 16 17:45:43 GMT 2023
PRIMARY
SMS_ID
100000079415
Created by admin on Sat Dec 16 17:45:44 GMT 2023 , Edited by admin on Sat Dec 16 17:45:44 GMT 2023
PRIMARY
EVMPD
SUB00151MIG
Created by admin on Sat Dec 16 17:45:43 GMT 2023 , Edited by admin on Sat Dec 16 17:45:43 GMT 2023
PRIMARY
ECHA (EC/EINECS)
278-321-2
Created by admin on Sat Dec 16 17:45:43 GMT 2023 , Edited by admin on Sat Dec 16 17:45:43 GMT 2023
PRIMARY
CAS
75820-08-5
Created by admin on Sat Dec 16 17:45:43 GMT 2023 , Edited by admin on Sat Dec 16 17:45:43 GMT 2023
PRIMARY
EPA CompTox
DTXSID6048834
Created by admin on Sat Dec 16 17:45:43 GMT 2023 , Edited by admin on Sat Dec 16 17:45:43 GMT 2023
PRIMARY
Related Record Type Details
Structure of ZIDAPAMIDE, (R)-
ENANTIOMER -> RACEMATE
Structure of ZIDAPAMIDE, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of ZIDAPAMIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966